Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Peginterferon Beta-1a in Relapsing Multiple Sclerosis
NCT00906399Phase 3Completed
- Sponsor
- Biogen
- Start
- Jun 2009
- Primary completion
- Oct 2012
- Modality
- Cytokines & Interferons
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of peginterferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoint: Annualized Relapse Rate at 1 year. Started Jun 2009; status: completed.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00906399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00906399.